Skip to main content

Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response

Publication ,  Conference
Keystone, E; Van der Heijde, D; Smolen, J; Weinblatt, M; Kvien, T; Strand, V; Ansari, Z; Goel, N; Combe, B
Published in: JOURNAL OF RHEUMATOLOGY
June 1, 2010

Duke Scholars

Published In

JOURNAL OF RHEUMATOLOGY

ISSN

0315-162X

Publication Date

June 1, 2010

Volume

37

Issue

6

Start / End Page

1333 / 1333

Location

Quebec, CANADA

Publisher

J RHEUMATOL PUBL CO

Conference Name

65th Annual Meeting of the Canadian-Rheumatology-Association

Related Subject Headings

  • Arthritis & Rheumatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1107 Immunology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Keystone, E., Van der Heijde, D., Smolen, J., Weinblatt, M., Kvien, T., Strand, V., … Combe, B. (2010). Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response. In JOURNAL OF RHEUMATOLOGY (Vol. 37, pp. 1333–1333). Quebec, CANADA: J RHEUMATOL PUBL CO.
Keystone, Edward, Desiree Van der Heijde, Joseph Smolen, Michael Weinblatt, Tore Kvien, Vibeke Strand, Zainab Ansari, Niti Goel, and Bernard Combe. “Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response.” In JOURNAL OF RHEUMATOLOGY, 37:1333–1333. J RHEUMATOL PUBL CO, 2010.
Keystone E, Van der Heijde D, Smolen J, Weinblatt M, Kvien T, Strand V, et al. Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response. In: JOURNAL OF RHEUMATOLOGY. J RHEUMATOL PUBL CO; 2010. p. 1333–1333.
Keystone, Edward, et al. “Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response.” JOURNAL OF RHEUMATOLOGY, vol. 37, no. 6, J RHEUMATOL PUBL CO, 2010, pp. 1333–1333.
Keystone E, Van der Heijde D, Smolen J, Weinblatt M, Kvien T, Strand V, Ansari Z, Goel N, Combe B. Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response. JOURNAL OF RHEUMATOLOGY. J RHEUMATOL PUBL CO; 2010. p. 1333–1333.

Published In

JOURNAL OF RHEUMATOLOGY

ISSN

0315-162X

Publication Date

June 1, 2010

Volume

37

Issue

6

Start / End Page

1333 / 1333

Location

Quebec, CANADA

Publisher

J RHEUMATOL PUBL CO

Conference Name

65th Annual Meeting of the Canadian-Rheumatology-Association

Related Subject Headings

  • Arthritis & Rheumatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1107 Immunology
  • 1103 Clinical Sciences